• Agrees to follow the trial protocol and visit schedule, has signed informed consent;

• Subjects must be ≥18 years of age at time of informed consent,regardless of gender;

• Patients with advanced/unresectable or metastatic pancreatic cancer or non-small cell lung cancer that requires histologically and/or cytologically confirmed according to the American Joint Committee on Cancer 8th edition; pancreatic cancer:Previous failure or intolerance of two or more lines of chemotherapy; NSCLC:Previous failure or intolerance of platinum-containing chemotherapy and anti-PD-1/PD-L1 monoclonal antibodies, regardless of combination therapy or sequential therapy, if the previous test for EGFR-sensitive mutations or ALK fusion genes is positive, treatment with a third-generation TKI must be failed or intolerant;

• At least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;

• ECOG≤1;

• Estimated life expectancy≥12 weeks;

• Adequate organ function, meet the following laboratory standards:

‣ ANC≥1.5×109/L;PLT≥90×109/L;

⁃ Hb≥90 g/L;

⁃ TBIL≤1.5×ULN, Patients with Gilbert's syndrome ; without liver metastases, AST and ALT ≤ 2.5×ULN;liver metastases, AST and ALT ≤5×ULN ;

⁃ Ccr≥50 mL/min;

⁃ INR≤1.5×ULN, APTT≤1.5×ULN;

• Males of childbearing potential and females of childbearing potential who are willing to use effective contraception since signing the informed consent until 6 months after the last dose of the trial drug. Females of childbearing potential must have a negative pregnancy test result within 7 days prior to the first dose.